The Food & Drug Administration’s role in biomedical innovation has, historically at least, been defined in pretty narrow terms: FDA is the gatekeeper. Until a new technology meets FDA’s standards for safety and efficacy, it can’t be marketed.
That is a powerful and important role, to be sure. But, fundamentally, a negative one: FDA’s job is to say “no” to most innovations, either in the context of an...